Gossrau Elke
DRK-Blutspendedienst Berlin gGmbH, Berlin.
Z Arztl Fortbild Qualitatssich. 2003 Nov;97(8-9):618-21.
The present paper deals with the physician's accountability during the implementation of hemotherapeutic measures. Since July 1, 1998 a Transfusion Law ('Transfusionsgesetz') regulates the clinical use of blood products in Germany in accordance with the guidelines established by the German Medical Association and the Paul Ehrlich Institute, which are regularly revised and adapted on the basis of current professional knowledge and technology. The therapeutic freedom allowed under the Code of Professional Medical Conduct is taken into account by the fact that the responsibility for hemotherapy in each individual case lies with the attending physician, no matter whether this applies to the diagnosis, the patient counselling or the administration of the transfusion itself. The administration of blood products, whether in hospital or a doctor's office, must follow certain quality-assumed rules governing transfusions as stipulated by the Transfusion Law. The responsibility for establishing regulations for hemotherapy and the introduction of a quality assurance system lies with the management of the treatment centre who appoint a specific physician as the hemovigilant ('Transfusionsverantwortlichen') who is responsible for meeting both these duties. The hemovigilant must be assisted by physicians specially appointed for transfusion measures (Transfusionsbeauftragte) who are responsible for the implementation of the hemotherapy regulations and quality assurance measures in the individual medical departments. As it is the hospital management's responsibility to ensure quality assurance, its duty also extends to monitoring the quality assurance system. Therefore a quality manager ('Qualitätsbeauftragter') will have to be appointed who must not be subject to directives. In case the management of the patient care centre does not fulfill the legal requirements or, for example, does not take action when shortcomings are discovered by the hemovigilant or quality manager that can only be dealt with by the management, then the organisational responsibility lies with the hospital management. Experience to date has demonstrated the success of the Transfusion Law. Whereas previously hospital managements have often failed to respond to suggestions for change or improvement, their attention may now be drawn to this law. This has led to blood products being increasingly used according to the same standards and keeping transfusing physicians on safe legal ground.
本文探讨了在实施血液治疗措施过程中医生的责任。自1998年7月1日起,一部《输血法》(“Transfusionsgesetz”)根据德国医学协会和保罗·埃利希研究所制定的指南对德国血液制品的临床使用进行规范,这些指南会根据当前的专业知识和技术定期修订和调整。《医学职业行为准则》所允许的治疗自由体现在,每一个病例的血液治疗责任都在于主治医生,无论这涉及诊断、患者咨询还是输血本身的实施。无论是在医院还是在医生办公室,血液制品的使用都必须遵循《输血法》规定的某些假定质量规则。制定血液治疗法规和引入质量保证体系的责任在于治疗中心的管理层,他们指定一名特定的医生作为血液警戒员(“Transfusionsverantwortlichen”),该医生负责履行这两项职责。血液警戒员必须得到专门指定负责输血措施的医生(“Transfusionsbeauftragte”)的协助,这些医生负责在各个医疗科室实施血液治疗法规和质量保证措施。由于确保质量保证是医院管理层的责任,其职责还延伸至对质量保证体系的监督。因此,必须任命一名质量经理(“Qualitätsbeauftragter”),且该经理不得受指令约束。如果患者护理中心的管理层未满足法律要求,或者例如在血液警戒员或质量经理发现只能由管理层处理的缺陷时不采取行动,那么组织责任就在于医院管理层。迄今为止的经验证明了《输血法》的成功。以前医院管理层常常对变革或改进建议不予回应,而现在他们可能会关注这部法律。这使得血液制品越来越多地按照相同标准使用,并使输血医生处于安全的法律地位。